INT262095

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.40
First Reported 2009
Last Reported 2009
Negated 3
Speculated 1
Reported most in Body
Documents 1
Total Number 9
Disease Relevance 2.58
Pain Relevance 0.44

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Cyp24a1) oxidoreductase activity (Cyp24a1)
Anatomy Link Frequency
intestine 3
liver 1
Cyp24a1 (Mus musculus)
Pain Link Frequency Relevance Heat
agonist 81 97.60 Very High Very High Very High
carbamazepine 9 82.64 Quite High
antiepileptic Drug 9 80.48 Quite High
Inflammation 153 39.44 Quite Low
Bile 351 38.08 Quite Low
Inflammatory stimuli 9 12.08 Low Low
antagonist 63 5.00 Very Low Very Low Very Low
Crohn's disease 54 5.00 Very Low Very Low Very Low
antidepressant 27 5.00 Very Low Very Low Very Low
dexamethasone 18 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Targeted Disruption 153 99.68 Very High Very High Very High
Rickets 72 98.86 Very High Very High Very High
Metabolic Bone Disease 9 85.92 High High
Inflammatory Bowel Disease 288 39.44 Quite Low
INFLAMMATION 108 33.44 Quite Low
Toxicity 36 32.08 Quite Low
Infection 18 32.08 Quite Low
Cancer 162 5.00 Very Low Very Low Very Low
Disease 90 5.00 Very Low Very Low Very Low
Breast Cancer 72 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This provided a mechanism to explain the low levels of CYP24 expression in tissues containing high levels of SXR. 1,25(OH)2D3-induced CYP24 expression was enhanced in SXR knockout mice, and treatment of humans with the SXR agonist rifampicin had no effect on intestinal CYP24 expression, despite marked CYP3A4 induction [Zhou et al., 2006a].
Positive_regulation (induced) of Gene_expression (expression) of CYP24 associated with targeted disruption and agonist
1) Confidence 0.40 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.15 Pain Relevance 0.05
Furthermore, feeding WT mice with diet containing the mouse SXR ligand, PCN, for two weeks strongly induced SXR target genes CYP3A11, GSTA1, and MDR1a expression, but failed to induce CYP24 expression in both liver and intestine (Zhou, C., unpublished observation).
Neg (failed) Positive_regulation (induce) of Gene_expression (expression) of CYP24 in intestine
2) Confidence 0.40 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.21 Pain Relevance 0.04
This provided a mechanism to explain the low levels of CYP24 expression in tissues containing high levels of SXR. 1,25(OH)2D3-induced CYP24 expression was enhanced in SXR knockout mice, and treatment of humans with the SXR agonist rifampicin had no effect on intestinal CYP24 expression, despite marked CYP3A4 induction [Zhou et al., 2006a].
Positive_regulation (enhanced) of Gene_expression (expression) of CYP24 associated with targeted disruption and agonist
3) Confidence 0.40 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.15 Pain Relevance 0.05
They conducted a series of in vitro and in vivo studies which were interpreted as providing evidence that a drug, which can activate SXR is likely to enhance CYP24 expression and the catabolism of 25(OH)D3, leading to vitamin D deficiency.
Positive_regulation (enhance) of Gene_expression (expression) of CYP24
4) Confidence 0.29 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.45 Pain Relevance 0.06
This suggests that enhanced CYP24 expression by SXR is unlikely to play an important role in the development of osteomalacia following long-term treatment with SXR activators.
Positive_regulation (enhanced) of Gene_expression (expression) of CYP24 associated with rickets
5) Confidence 0.29 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.40 Pain Relevance 0
It was later shown that activation of SXR did not induce CYP24 expression in vitro or in vivo, nor did it transactivate the CYP24 promoter [Zhou et al., 2006a].
Neg (not) Positive_regulation (induce) of Gene_expression (expression) of CYP24
6) Confidence 0.29 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.14 Pain Relevance 0.03
To reveal the mechanism of drug-induced osteomalacia, several groups recently investigated the impact of SXR activation on CYP24 gene expression in vitro and in vivo.
Spec (investigated) Positive_regulation (activation) of Gene_expression (expression) of CYP24 gene associated with rickets
7) Confidence 0.29 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.45 Pain Relevance 0.08
Pascussi et al. first suggested that activation of SXR can enhance the expression of the VDR target gene, CYP24, which would increase the catabolism of 1,25(OH)2D3; thereby, leading to drug-induced osteomalacia [Pascussi et al., 2005].
Positive_regulation (enhance) of Gene_expression (expression) of CYP24 associated with rickets
8) Confidence 0.29 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.44 Pain Relevance 0.08
Furthermore, feeding WT mice with diet containing the mouse SXR ligand, PCN, for two weeks strongly induced SXR target genes CYP3A11, GSTA1, and MDR1a expression, but failed to induce CYP24 expression in both liver and intestine (Zhou, C., unpublished observation).
Neg (failed) Positive_regulation (induce) of in liver Gene_expression (expression) of CYP24 in intestine
9) Confidence 0.13 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.21 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox